0.9302

0.02% 0.0002

After Hours: .96 0.0298 +3.20%

Oncolytics Biotech Inc (ONCY)

Overview News Price History Why ONCY Down? Discussions Forecast Stock Split

Oncolytics Biotech Inc stock is traded at $0.9302, with a volume of 109.38K. It is up +0.02% in the last 24 hours and down -21.83% over the past month. Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Previous Close:

$0.93

Open:

$0.92

24h Volume:

109.38K

Relative Volume:

0.25

Market Cap:

$71.69M

Revenue:

Net Income/Loss:

$-20.59M

P/E Ratio:

-2.7784

EPS:

-0.3348

Net Cash Flow:

$-17.99M

1W Performance:

-2.50%

1M Performance:

-21.83%

6M Performance:

-14.66%

1Y Performance:

-37.15%

1-Day Range:

$0.92

$0.95

1-Week Range:

$0.91

$0.9799

52-Week Range:

$0.8401

$1.53

Oncolytics Biotech Inc Stock (ONCY) Company Profile

Name

Oncolytics Biotech Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

Address

Employee

Twitter

@oncolytics

Next Earnings Date

2024-11-04

Latest SEC Filings

ONCY's Discussions on Twitter

Compare ONCY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ONCY Oncolytics Biotech Inc	0.9302	71.69M	0	-20.59M	-17.99M	-0.3046
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-22	Initiated	Maxim Group	Buy
Feb-17-21	Initiated	H.C. Wainwright	Buy

Oncolytics Biotech Inc Stock (ONCY) Latest News

Nov 26, 2024

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference - Quantisnow

Nov 26, 2024

Nov 24, 2024

Oncolytics Biotech® to Host Conference Call to Discuss Third Qua - GuruFocus.com

Nov 24, 2024

Nov 18, 2024

Oncolytics Biotech (NASDAQ:ONCY) Downgraded to Moderate Buy Rating by Leede Financial - Defense World

Nov 17, 2024

Oncolytics Biotech (TSE:ONC) Upgraded at Raymond James - Defense World

Nov 17, 2024

Oncolytics Biotech (NASDAQ:ONCY) Upgraded at Raymond James - Defense World

Nov 17, 2024

Nov 16, 2024

Oncolytics Biotech (TSE:ONC) Upgraded by Raymond James to Moderate Buy Rating - MarketBeat

Nov 16, 2024

Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Moderate Buy" Rating by Leede Financial - MarketBeat

Nov 16, 2024

Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James - MarketBeat

Nov 16, 2024

Research Analysts Issue Forecasts for ONCY FY2024 Earnings - Defense World

Nov 16, 2024

Nov 15, 2024

FY2028 EPS Estimates for TSE:ONC Boosted by HC Wainwright - MarketBeat

Nov 15, 2024

Raymond James Has Bearish Forecast for ONCY FY2024 Earnings - MarketBeat

Nov 15, 2024

Nov 14, 2024

Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon - Baystreet.ca

Nov 14, 2024

Oncolytics Biotech (NASDAQ:ONCY) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 14, 2024

Biotech Companies' Q3 Updates: Promising Cancer Treatments On The Horizon - Barchart

Nov 14, 2024

Earnings call: Oncolytics Biotech eyes accelerated approval for pelareorep By Investing.com - Investing.com Nigeria

Nov 14, 2024

Nov 13, 2024